Stay updated with breaking news from Sci Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for pa...
RNA Gene Writing™ platform demonstrates continued advances in rewriting to correct pathogenic mutations responsible for phenylketonuria (PKU), alpha-1...
SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive...
Innosuisse supports 53 companies out of 752 applications with total CHF 112MAraris’ awarded grant will be used to support further development and...
Hires and promotions at agencies around the world.